About Concordia International (TSE:CXR)
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:CXR
CUSIPN/A
Phone+1-905-8425150
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-44.94%
Return on EquityN/A
Return on Assets-10.59%
Miscellaneous
EmployeesN/A
Outstanding Shares51,284,000
Concordia International (TSE:CXR) Frequently Asked Questions
What is Concordia International's stock symbol?
Concordia International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International's earnings last quarter?
Concordia International (TSE:CXR) announced its earnings results on Thursday, March, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.44. The company had revenue of $190.77 million for the quarter. View Concordia International's Earnings History.
When is Concordia International's next earnings date?
Who are some of Concordia International's key competitors?
Some companies that are related to Concordia International include Rubicon Minerals (RMX), Tree Island Steel (TSL), Bellatrix Exploration (BXE), Journey Energy (JOY), Temple Hotels (TPH), Colabor Group (GCL), Platinum Group Metals (PTM), Phoscan Chemical (PRQ), NexJ Systems (NXJ), Trimel Pharmaceuticals (ASP), Fortress Paper (FTP), Trez Capital Limited Partnership (TZZ), Primero Mining (P), Chinook Energy (CKE), Perpetual Energy (PMT), Eastern Platinum (ELR), McCoy Global (MCB) and FORACO International S.A (FAR).
Who are Concordia International's key executives?
Concordia International's management team includes the folowing people:
- Mr. Allan Oberman, CEO & Director (Age 60)
- Mr. Francesco Tallarico, Chief Legal Officer & Sec.
- Mr. Adrian A. de Saldanha, Exec. (Age 57)
- Mr. Adeel Ahmad, Chief Financial Officer of Concordia International Segment
- Mr. David J. Price, Chief Financial Officer (Age 55)
Has Concordia International been receiving favorable news coverage?
News stories about CXR stock have been trending somewhat positive this week, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Concordia International earned a daily sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the company an impact score of 44.88 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Concordia International?
Shares of CXR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International's stock price today?
One share of CXR stock can currently be purchased for approximately C$0.65.
How big of a company is Concordia International?
Concordia International has a market capitalization of C$38.43 million.
How can I contact Concordia International?
Concordia International's mailing address is 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada. The company can be reached via phone at +1-905-8425150.
MarketBeat Community Rating for Concordia International (CXR)
MarketBeat's community ratings are surveys of what our community members think about Concordia International and other stocks. Vote "Outperform" if you believe CXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Concordia International (TSE:CXR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | Sell | Sell |
| Consensus Rating Score: | N/A | N/A | 1.00 | 1.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 4 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | C$13.50 |
| Price Target Upside: | N/A | N/A | N/A | 409.43% upside |
Concordia International (TSE:CXR) Consensus Price Target History
Concordia International (TSE:CXR) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Concordia International (TSE:CXR) Earnings History and Estimates Chart
Concordia International (TSE CXR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2018 | | | | | | | | |
| 3/8/2018 | Q4 2017 | C$0.08 | C($0.36) | | C$190.77 million | View | N/A |  |
| 11/14/2017 | Q3 2017 | C$0.17 | C$0.08 | | C$193.95 million | View | N/A | |
| 8/11/2017 | Q2 2017 | C$0.19 | C$0.26 | | C$216.27 million | View | N/A | |
| 5/10/2017 | Q1 2017 | C$0.70 | C($0.49) | | C$212.51 million | View | N/A | |
| 3/15/2017 | Q4 2016 | | C$0.08 | | C$227.49 million | View | N/A | |
| 11/7/2016 | Q3 2016 | C$1.30 | C($0.43) | | C$241.92 million | View | N/A | |
| 8/12/2016 | Q2 2016 | | C$1.56 | | C$298.70 million | View | N/A | |
| 5/13/2016 | Q1 2016 | C$1.86 | C$1.71 | | C$314.05 million | View | N/A | |
| 3/23/2016 | Q4 2015 | C$1.99 | C$1.44 | C$259.15 million | C$256.29 million | View | N/A | |
| 11/12/2015 | Q3 2015 | C$1.73 | C$1.70 | C$125.26 million | C$124.17 million | View | N/A | |
| 8/13/2015 | Q2 | C$1.06 | C$1.04 | C$87.41 million | C$95.34 million | View | Listen | |
| 5/14/2015 | Q1 2015 | C$0.51 | C$0.64 | C$54.03 million | C$43.67 million | View | N/A | |
| 3/19/2015 | Q4 2014 | C$0.73 | C$0.94 | C$52.77 million | C$54.76 million | View | N/A | |
| 11/13/2014 | Q3 2014 | C$0.58 | C$0.40 | C$40.08 million | C$41.25 million | View | N/A | |
| 8/13/2014 | | C$0.19 | C($0.03) | C$24.42 million | C$28.49 million | View | N/A | |
| 5/15/2014 | Q1 2014 | | C($0.10) | | C$18.32 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Concordia International (TSE:CXR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/13/2016 | Quarterly | $0.0750 | 1.14% | 7/13/2016 | 7/29/2016 | 7/29/2016 |
| 4/13/2016 | Quarterly | $0.0750 | 0.95% | 4/13/2016 | 4/29/2016 | 4/29/2016 |
| 1/13/2016 | Quarterly | $0.0750 | 0.53% | 1/13/2016 | 1/29/2016 | 1/29/2016 |
| 10/13/2015 | Quarterly | $0.0750 | 0.62% | 10/13/2015 | 10/30/2015 | 10/30/2015 |
| 7/13/2015 | Quarterly | $0.0750 | 0.32% | 7/13/2015 | 7/31/2015 | 7/31/2015 |
| 4/13/2015 | Quarterly | $0.0750 | 0.35% | 4/13/2015 | 4/30/2015 | 4/30/2015 |
| 1/13/2015 | Quarterly | $0.0750 | 0.61% | 1/13/2015 | 1/31/2015 | 1/31/2015 |
| 10/10/2014 | Quarterly | $0.0750 | 0.76% | 10/10/2014 | 10/31/2014 | 10/31/2014 |
| 7/11/2014 | Quarterly | $0.0750 | 0.92% | 7/11/2014 | 7/31/2014 | 7/31/2014 |
(Data available from 1/1/2013 forward)
Concordia International (TSE CXR) Insider Trading and Institutional Ownership History
Concordia International (TSE CXR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2018 | John Beighton | Director | Sell | 147,000 | C$0.68 | C$99,960.00 | | |
| 3/19/2018 | John Beighton | Director | Sell | 34,000 | C$0.75 | C$25,500.00 | | |
| 5/25/2017 | Erin Colleen O'neil | Director | Sell | 191 | C$1.74 | C$332.34 | | |
| 5/16/2017 | Graeme Neville Duncan | Director | Sell | 7,065 | C$1.91 | C$13,494.15 | | |
| 2/1/2016 | Mark Laurence Thompson | Director | Buy | 60 | C$28.77 | C$1,726.20 | | |
| 11/17/2015 | Rochelle Fuhrmann | Director | Buy | 2,000 | C$31.67 | C$63,340.00 | | |
| 11/17/2015 | Wayne Walter Kreppner | Insider | Buy | 3,000 | C$43.67 | C$131,010.00 | | |
| 11/16/2015 | Mark Laurence Thompson | Director | Buy | 23,150 | C$43.36 | C$1,003,702.98 | | |
| 10/27/2015 | Edward Borkowski | Director | Buy | 4,000 | C$30.43 | C$121,720.00 | | |
| 7/23/2015 | Jordan Kupinsky | Director | Sell | 43,000 | C$103.70 | C$4,459,272.00 | | |
| 7/17/2015 | Wayne Walter Kreppner | Insider | Sell | 4,800 | C$103.00 | C$494,400.00 | | |
| 7/3/2015 | Jordan Kupinsky | Director | Sell | 10,800 | C$92.21 | C$995,884.20 | | |
| 7/2/2015 | Jordan Kupinsky | Director | Sell | 45,900 | C$92.05 | C$4,224,934.35 | | |
| 6/26/2015 | Robert Steven Altman | Insider | Sell | 62,500 | C$93.93 | C$5,870,893.75 | | |
| 6/22/2015 | John-Michel Huss | Director | Sell | 5,000 | C$92.00 | C$460,000.00 | | |
| 6/19/2015 | John-Michel Huss | Director | Sell | 4,300 | C$90.00 | C$387,000.00 | | |
| 6/11/2015 | John-Michel Huss | Director | Sell | 4,500 | C$90.02 | C$405,076.50 | | |
| 5/27/2015 | Saldanha Adrian De | Insider | Buy | 1,000 | C$80.61 | C$80,610.00 | | |
| 5/19/2015 | Adeel Ahmad | Insider | Sell | 25,000 | C$83.80 | C$2,094,890.00 | | |
| 10/31/2014 | James Christopher Reebals | Director | Sell | 7,500 | C$37.25 | C$279,360.75 | | |
| 10/30/2014 | James Christopher Reebals | Director | Sell | 7,500 | C$37.06 | C$277,926.75 | | |
| 10/29/2014 | James Christopher Reebals | Director | Sell | 5,000 | C$37.07 | C$185,336.50 | | |
(Data available from 1/1/2013 forward)
Concordia International (TSE CXR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Edited Transcript of CXR.TO earnings conference call or presentation 8-Mar-18 1:30pm GMT
finance.yahoo.com - April 12 at 9:24 AM |
 | Concordia International Corp (CXR) Director Sells C$99,960.00 in Stock
www.americanbankingnews.com - March 26 at 4:10 PM |
| John Beighton Sells 34,000 Shares of Concordia International Corp (CXR) Stock
www.americanbankingnews.com - March 20 at 1:23 PM |
 | Orthofix Int'l (OFIX) Names John Sicard to Board of Directors
www.streetinsider.com - March 13 at 6:56 PM |
 | Orthofix Announces Appointment of John Sicard to Board of Directors
www.bizjournals.com - March 13 at 6:56 PM |
| Concordia International Corp. Announces Fourth Quarter and Fiscal 2017 Results
finance.yahoo.com - March 8 at 8:54 AM |
| Today’s Research Reports on Concordia International, GeneNews, Medicure and Calyx Ventures
finance.yahoo.com - March 5 at 8:45 AM |
| Concordia International (CXR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM |
| Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2017 Results
finance.yahoo.com - February 21 at 8:48 AM |
| Form 6-K Concordia International For: Feb 15
www.streetinsider.com - February 15 at 5:03 PM |
 | Concordia International Corp. Comments on CMA's Decision to ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 8:11 AM |
| Concordia International Corp. Comments on CMA's Decision to Close its Investigation of Fusidic Acid
finance.yahoo.com - February 15 at 8:11 AM |
| Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement
finance.yahoo.com - December 1 at 5:03 PM |
| Concordia International Corp. :CXR-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 23, 2017
finance.yahoo.com - November 23 at 4:11 PM |
| Edited Transcript of CXR.TO earnings conference call or presentation 14-Nov-17 1:30pm GMT
finance.yahoo.com - November 14 at 11:09 PM |
| Concordia International Corp (CXR) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 7 at 9:06 AM |
| Concordia International Corp. Announces Release Date for Third Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - November 2 at 4:46 AM |
 | TSX Creeps Closer To Record Highs -- Canadian Commentary
www.rttnews.com - October 20 at 7:12 PM |
| IIROC Trade Resumption - CXR
finance.yahoo.com - October 20 at 7:11 PM |
 | Update: TSX Posts Modest 30-Point Gain in Broad-Based Advance Led by Financials & Industrials
www.nasdaq.com - October 12 at 5:20 AM |
| Canadian Stocks Turn Positive After EIA Report - Canadian Commentary
www.nasdaq.com - October 4 at 11:20 AM |
| Canadian Stocks Are Recovering Following Yesterday's Loss - Canadian Commentary
www.nasdaq.com - September 27 at 6:50 PM |
| ETFs with exposure to Concordia International Corp. : September 6, 2017
finance.yahoo.com - September 6 at 12:19 AM |
| Concordia International Corp. Announces Release Date for DELIVER Strategy - PR Newswire (press release)
www.prnewswire.com - September 1 at 11:00 PM |
| Canadian Stocks Are Rising On Strong GDP Data - Canadian Commentary
www.nasdaq.com - August 31 at 5:37 PM |
| Concordia International Corp. :CXR-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 18, 2017
finance.yahoo.com - August 18 at 5:40 PM |
| RedHill Biopharma Announces US Commercialization Agreement for FDA-Approved GI Product Esomeprazole ... - Nasdaq
www.nasdaq.com - August 17 at 4:32 PM |
 | SHAREHOLDER ALERT: Morganti Legal, PC Advises Shareholders of Concordia International Corp. of a Motion ... - Business Wire (press release)
www.businesswire.com - August 15 at 6:24 PM |
| Edited Transcript of CXR.TO earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 11:12 PM |
| Concordia International Corp (TSE:CXR) Set to Announce Earnings on Friday
www.americanbankingnews.com - August 4 at 7:12 AM |
| Concordia International Corp. :CXR-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 7:15 PM |
| Short seller Cohodes hits Canada again with latest target -Exchange Income
www.nasdaq.com - July 5 at 6:28 PM |
 | Concordia Shares Lead TSX Gainers on Corporate Update
www.baystreet.ca - June 22 at 10:32 AM |
| Concordia International Corp. Announces Results of First CMA Stop/Go Decision - PR Newswire (press release)
www.prnewswire.com - May 31 at 9:39 PM |
| Concordia International Corp. Announces Two New Appointments to ... - PR Newswire (press release)
www.prnewswire.com - May 4 at 8:02 AM |
| Canadian Stocks Are Extending Recent Losses - Canadian Commentary
www.nasdaq.com - April 13 at 11:46 AM |
| Canadian Stocks Are Paring Early Gains - Canadian Commentary
www.nasdaq.com - March 17 at 9:58 PM |
| Stocks Rally On Oil Rebound, Sober Fed -- Canadian Commentary
www.nasdaq.com - March 15 at 5:04 PM |
| Q4 2016 Concordia International Corp Earnings Release - Before Market Open
biz.yahoo.com - March 15 at 9:47 AM |
| RedHill Biopharma's Co-Promotion Partner Concordia Announces ... - Nasdaq
www.nasdaq.com - March 7 at 4:34 PM |
 | Profile: Concordia International Corp (CXR.TO)
www.reuters.com - February 7 at 10:47 PM |
| Canadian Stocks Are Extending Their Losses In Early Trade - Canadian Commentary - Nasdaq
www.nasdaq.com - January 31 at 5:15 PM |
| TSX Slightly Higher, Blackberry Makes Bet On Self-driving Cars
www.rttnews.com - December 20 at 5:23 PM |
Concordia International (TSE:CXR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Concordia International (TSE CXR) Stock Chart for Friday, April, 20, 2018
Loading chart…
